Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GNT-0003 by Genethon for Crigler-Najjar Syndrome: Likelihood of Approval
GNT-0003 is under clinical development by Genethon and currently in Phase II for Crigler-Najjar Syndrome. According to GlobalData, Phase II...